NEW YORK--(BUSINESS WIRE)--June 6, 2006--Amphion Innovations plc (LSE:AMP - News; "Amphion"), the developer of technology and life sciences businesses, announces that it has signed a memorandum of understanding (MoU) with Myconostica Ltd which grants Amphion an exclusivity period in which to agree final terms on an investment in Myconostica as its next Partner Company. Myconostica is a spin out of the University of Manchester, with close links to other leading research institutions in the US and Europe, which is developing products focused on the more speedy, accurate and cost effective diagnosis of infectious diseases.
